These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1359619)

  • 21. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
    Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
    Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients.
    De Simone C; Tzantzoglou S; Santini G; Vullo V; di Orio F; Leuter C; Jirillo E; Delia S
    Immunopharmacol Immunotoxicol; 1991; 13(3):447-58. PubMed ID: 1940058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combined toxicity of azidothymidine and antimycobacterial agents. A retrospective study.
    Kavesh NG; Holzman RS; Seidlin M
    Am Rev Respir Dis; 1989 May; 139(5):1094-7. PubMed ID: 2712436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of reduced doses of azidothymidine in Japanese patients with human immunodeficiency virus type 1 infection.
    Kimura S; Oka S; Toyoshima T; Hirabayashi Y; Kikuchi Y; Mitamura K; Shimada K
    Intern Med; 1992 Jul; 31(7):871-6. PubMed ID: 1360277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
    Gallant JE; Moore RD; Keruly J; Richman DD; Chaisson RE
    J Infect Dis; 1995 Aug; 172(2):346-52. PubMed ID: 7622876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response of AIDS-related thrombocytopenia to intravenous and oral azidothymidine (3'-azido-3'-deoxythymidine).
    Gottlieb MS; Wolfe PR; Chafey S
    AIDS Res Hum Retroviruses; 1987; 3(2):109-14. PubMed ID: 3113461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zidovudine: experience at the Newcastle Haemophilia Centre.
    Jones P
    J Infect; 1989 Jan; 18 Suppl 1():53-8. PubMed ID: 2783716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group.
    Swanson CE; Cooper DA
    AIDS; 1990 Aug; 4(8):749-57. PubMed ID: 1979744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals.
    Hollander H; Lifson AR; Maha M; Blum R; Rutherford GW; Nusinoff-Lehrman S
    Am J Med; 1989 Dec; 87(6):628-32. PubMed ID: 2574006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zidovudine treatment for anti-HIV positive haemophiliacs.
    Lim SG; Lee CA; Kernoff PB
    Clin Lab Haematol; 1990; 12(4):367-78. PubMed ID: 2081377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival.
    Haug C; Müller F; Aukrust P; Frøland SS
    J Infect Dis; 1994 Apr; 169(4):889-93. PubMed ID: 7907645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase of hemoglobin A2 in human immunodeficiency virus-1-infected patients treated with zidovudine.
    Routy JP; Monte M; Beaulieu R; Toma E; St-Pierre L; Dumont M
    Am J Hematol; 1993 Jun; 43(2):86-90. PubMed ID: 8342556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine.
    Bacchetti P; Moss AR; Andrews JC; Jacobson MA
    J Acquir Immune Defic Syndr (1988); 1992; 5(7):732-6. PubMed ID: 1535375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian multicenter azidothymidine trial: AZT pharmacokinetics.
    Child S; Montaner J; Tsoukas C; Fanning M; Le T; Wall RA; Ruedy J
    J Acquir Immune Defic Syndr (1988); 1991; 4(9):865-70. PubMed ID: 1895207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of zidovudine on platelet count in HIV-infected individuals.
    Montaner JS; Le T; Fanning M; Gelmon K; Tsoukas C; Falutz J; O'Shaughnessy M; Wainberg MA; Ruedy J
    J Acquir Immune Defic Syndr (1988); 1990; 3(6):565-70. PubMed ID: 2187071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic and renal effects of azidothymidine and acyclovir on pregnant rats.
    Mamede JA; Oliveira-Filho RM; Simo s MJ; Mora OA; Espiridião SKulay L
    Clin Exp Obstet Gynecol; 2000; 27(3-4):227-30. PubMed ID: 11214960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS.
    Mocchegiani E; Veccia S; Ancarani F; Scalise G; Fabris N
    Int J Immunopharmacol; 1995 Sep; 17(9):719-27. PubMed ID: 8582783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.
    Gelmon K; Montaner JS; Fanning M; Smith JR; Falutz J; Tsoukas C; Gill J; Wells G; O'Shaughnessy M; Wainberg M
    AIDS; 1989 Sep; 3(9):555-61. PubMed ID: 2528969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semen analysis in human immunodeficiency virus infection.
    Crittenden JA; Handelsman DJ; Stewart GJ
    Fertil Steril; 1992 Jun; 57(6):1294-9. PubMed ID: 1601153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.